Growing community of inventors

Tarragona, Spain

Fernando Bravo

Average Co-Inventor Count = 6.86

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Fernando BravoJohn A Beutler (2 patents)Fernando BravoAntonio Echavarren (2 patents)Fernando BravoWilliam J Chain (1 patent)Fernando BravoDavid John Beech (1 patent)Fernando BravoZhenhua Wu (1 patent)Fernando BravoJean-Simon Suppo (1 patent)Fernando BravoHussein Rubaiy (1 patent)Fernando BravoLaura Lopez (1 patent)Fernando BravoLorena Riesgo (1 patent)Fernando BravoTanya Tannaquil Ransom (1 patent)Fernando BravoWilliam Chain (0 patent)Fernando BravoLaura Lopez (0 patent)Fernando BravoAntonio M Echavarren (0 patent)Fernando BravoFernando Bravo (2 patents)John A BeutlerJohn A Beutler (12 patents)Antonio EchavarrenAntonio Echavarren (3 patents)William J ChainWilliam J Chain (2 patents)David John BeechDavid John Beech (2 patents)Zhenhua WuZhenhua Wu (1 patent)Jean-Simon SuppoJean-Simon Suppo (1 patent)Hussein RubaiyHussein Rubaiy (1 patent)Laura LopezLaura Lopez (1 patent)Lorena RiesgoLorena Riesgo (1 patent)Tanya Tannaquil RansomTanya Tannaquil Ransom (1 patent)William ChainWilliam Chain (0 patent)Laura LopezLaura Lopez (0 patent)Antonio M EchavarrenAntonio M Echavarren (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. National Institutes of Health, a Component of the US Dept. of Health & Human Services (2 from 3,435 patents)

2. Universitat Rovira I Virgili (2 from 9 patents)

3. University of Delaware (1 from 430 patents)

4. University of Leeds (1 from 108 patents)

5. Fundacio Institut Catala D'investigacio Quimica (iciq) (1 from 8 patents)

6. Fundacio Institut Catala D'investigacio Quimica (1 from 3 patents)


2 patents:

1. 11098054 - Englerin derivatives for treatment of cancer

2. 10287297 - Epoxyazulene derivatives useful for treating cancer and diabetes

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/9/2025
Loading…